Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial
Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial
About this item
Full title
Author / Creator
Lewis, Gavin A. , Dodd, Susanna , Clayton, Dannii , Bedson, Emma , Eccleson, Helen , Schelbert, Erik B. , Naish, Josephine H. , Jimenez, Beatriz Duran , Williams, Simon G. , Cunnington, Colin , Ahmed, Fozia Zahir , Cooper, Anne , Rajavarma Viswesvaraiah , Russell, Stuart , McDonagh, Theresa , Williamson, Paula R. and Miller, Christopher A.
Publisher
New York: Nature Publishing Group US
Journal title
Language
English
Formats
Publication information
Publisher
New York: Nature Publishing Group US
Subjects
More information
Scope and Contents
Contents
In heart failure with preserved ejection fraction (HFpEF), the occurrence of myocardial fibrosis is associated with adverse outcome. Whether pirfenidone, an oral antifibrotic agent without hemodynamic effect, is efficacious and safe for the treatment of HFpEF is unknown. In this double-blind, phase 2 trial (
NCT02932566
), we enrolled patient...
Alternative Titles
Full title
Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial
Authors, Artists and Contributors
Author / Creator
Dodd, Susanna
Clayton, Dannii
Bedson, Emma
Eccleson, Helen
Schelbert, Erik B.
Naish, Josephine H.
Jimenez, Beatriz Duran
Williams, Simon G.
Cunnington, Colin
Ahmed, Fozia Zahir
Cooper, Anne
Rajavarma Viswesvaraiah
Russell, Stuart
McDonagh, Theresa
Williamson, Paula R.
Miller, Christopher A.
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2560960382
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2560960382
Other Identifiers
ISSN
1078-8956
E-ISSN
1546-170X
DOI
10.1038/s41591-021-01452-0
